ABVC BioPharma, Inc. announced that the Science Park Administration in Taiwan approved the plan for setting up a pilot Good Manufacturing Practice (GMP) facility to produce Vitargus(R), a product in retinal detachment surgery, and to pursue the process development work for manufacturing optimization. The plan, proposed by ABVC's Taiwan affiliate and co-development partner, BioFirst Corporation, is to upgrade Vitargus'(R) manufacturing processes so that ultimately, it can handle the global market supply of Vitargus(R). The factory is located in Hsinchu Biomedical Science Park, Taiwan and BioFirst Corporation is targeting to complete the construction in 2024.

BioFirst Corporation is dedicated to researching, developing, manufacturing, marketing, and securing exclusive global rights for innovative patented medical products. BioFirst Corporation has secured exclusive global rights for three Ophthalmology products from the National Health Research Institutes (NHRI). Among them, the company believe that Vitargus(R) a Vitreous Substitute, is the most advanced R&D product and is the first biodegradable hydrogel product used in retinal detachment surgery.